Nino Landler retweeted
Great progress! We've reached 1/3 enrollment in the COLFIB trial: 167/500 afib patients! 🎉 This trial, randomizing between placebo & colchicine, aims to prove colchicine's cardioprotective capabilities. Stay tuned for results!#COLFIB #Arrhythmia #Colchicine @CTCPR_
@TorBiering
Nino Landler retweeted
🫀my first PhD article - our #CARISMA sub study on the risk of #arrhythmias after #ACS according to mode of #revascularization - has made it to the new 2025 ACC/AHA guideline for the management of #ACS 👇
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes #AHAJournals
ahajournals.org/doi/10.1161/…
Nino Landler retweeted
Our most recent paper by the brilliant Daniel Modin on the impact of Influenza in patients with HF just published in @JACCJournals 👇
@CTCPR_ @koebenhavns_uni
Around 2.6% of all deaths and 5% of all hospitalizations with #influenza or #pneumonia may be caused by influenza in patients with #heartfailure. jacc.org/doi/10.1016/j.jacc.…
#JACC #FightFlu @niklasdj1 @scottdsolomon
Nino Landler retweeted
DANFLU-2 is yet again breaking all records on pragmatic trial conduct. We randomized more than 50000 Danes in just the first week of this year’s inclusion.
In total 340000 Danes will be randomized over 3 seasons.
The results will be out next summer!
clinicaltrials.gov/study/NCT…
Nino Landler retweeted
Simultaneously publication by Jacob Christensen from @CTCPR_ at #ESCCongress
Relative Effectiveness of High-Dose vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults with Cardiovascular Disease: A Prespecified Analysis of the DANFLU-1 Randomized Clinical Trial 👇
#ESCCongress Sim Pub from @Torbiering et al: Relative Effectiveness of High-Dose vs Standard-Dose Quadrivalent Influenza Vaccine in Older Adults with CVD: A Prespecified Analysis of the DANFLU-1 Randomized Clinical Trial ahajournals.org/doi/10.1161/… #AHAJournals @CTCPR_ #CircCQO
Nino Landler retweeted
Today we finalized the inclusion of DECODE-CKD, a mechanistic RCT to study the cardioprotective effects of SGLT2i in people with chronic kidney disease.
@TorBiering @CTCPR_
1/3
Nino Landler retweeted
Congratulations 👏 to @katjabartholdy and the rest of the amazing @CTCPR_ team for finalizing recruitment of our DECODE-CKD trial. Results will be ready in 6 months. Please read more about the trial in the design paper. See link below 👇
journals.lww.com/kidney360/f…
Today we finalized the inclusion of DECODE-CKD, a mechanistic RCT to study the cardioprotective effects of SGLT2i in people with chronic kidney disease.
@TorBiering @CTCPR_
1/3
Nino Landler retweeted
New study: prevalence & implications of HF stages in patients with CKD 🚨
prospective cohort of 825 CKD pts
HF stages A to D ⬆️ with ⬆️ CKD stages
HF may be underdx in CKD: 8.8% had diagnosis but 15.3% had HF stage C/D!!🫀
@TorBiering @JACCJournals
authors.elsevier.com/a/1jKM-…
Nino Landler retweeted
Awesome to present the main results of the NUDGE-FLU-CHRONIC trial as LBCT yesterday at #ESCMIDGlobal!
Our nudges increased flu vacc uptake from 28% to 40% in 18-64 yos with chronic diseases in Denmark, corresponding to 25,000 additional vaccinees! – at Barcelona, Spain
Nino Landler retweeted
Our most recent analysis from the NUDGE-FLU trial published today in @AnnalsofIM
@CTCPR_ @HerlevGentofte @CopCard @RigsHeart @BiomedUCPH @Stenodiabetes – at Copenhagen, Denmark
#NUDGEFLU: A Nationwide Pragmatic Implementation RCT to Boost Influenza Vaccination in ~1M Older 🇩🇰 Citizens led by @niklasdj1 & @TorBiering
Early Implementation Outcomes in @TheLancet
thelancet.com/journals/lance…
Clinical Outcomes out today in @AnnalsofIM!
acpjournals.org/doi/10.7326/…
Nino Landler retweeted
Our most recent analysis from the NUDGE-FLU trial assessing the effect of NUDGES to increase flu vaccine uptake amongst DM patients just published in @JAMA_current Open. Analysis lead by the brilliant @matslassen 👏 – at Gentofte, Danmark
Analysis of the NUDGE-FLU study reveals electronic nudges designed to boost #influenza vaccination were more effective in older adults without #diabetes, highlighting the need for tailored approaches in diabetes populations.
hcplive.com/view/electronic-…
Nino Landler retweeted
Today we reached yet another important milestone in the DANFLU-2 trial. We randomized more than 150.000 participants in just 3 weeks. The DANFLU-2 trial is revolutionizing how to use nationwide registries to execute large scale outcome RCT’s @CIRL_DK
clinicaltrials.gov/study/NCT…… – at Gentofte, Danmark
Today we reached an important milestone for DANFLU-2. We randomized more than 100.000 in just 2 weeks. I believe this is the largest number of randomized individuals in any RCT using individual randomization. What a remarkable teamwork at @CIRL_DK
More: clinicaltrials.gov/study/NCT…
Nino Landler retweeted
Today we reached an important milestone for DANFLU-2. We randomized more than 100.000 in just 2 weeks. I believe this is the largest number of randomized individuals in any RCT using individual randomization. What a remarkable teamwork at @CIRL_DK
More: clinicaltrials.gov/study/NCT… – at Gentofte, Danmark
Nino Landler retweeted
Cardiac conduction system pacing - the new black? @CardiologyZuh is ready to takeoff🚀 #EPeeps
Nino Landler retweeted
Ready for a case report?
In this @CircHF article the authors @ersboell_mads @FinnGustafsson et al. present a rare case of a 59-year-old female w/ high output #HF caused by a renal clear cell carcinoma 🫀😮💨 one to remember in the diagnostic work-around in this patient group‼️
Nino Landler retweeted
HF and DM frequently co-exist w/ increasingly overlapping treatment options. Out in @JCardFail, from @American_Heart #GWTG #TRANSLATEHF, we examined medical therapy in >35,000 pts with DM + HF from 2014-2019. @scottdsolomon
onlinejcf.com/article/S1071-…
Nino Landler retweeted
High-sensitivity troponin-I and risk of heart failure in individuals with suspected acute coronary syndrome by superstar @ChristinaBFA at #ESC2023 #DCS_ESC23 @RigsHeart @KragholmK @DLBHATTMD @mvaduganathan
Nino Landler retweeted
#milestone
Yesterday, the last patients was randomized in the #DanGerShock trial by the Copenhagen team!
Patient no. 360 💪🏻
… follow-up results expected in early 2024!
DangerShock is lead by PI Jacob E. Møller
@RigsHeart
Nino Landler retweeted
A recent published study by dr. @bowinkel75 and colleagues📚The study examined #CardiacArrest survivors with bundle branch block (BBB) but no IHD🏥Findings reveal high prevalence of LBBB among survivors and lower left ventricular ejection fraction compared to other BBB types🫀
Nino Landler retweeted
Huge congrats to Prof. Jacob Eifer Møller with the @novonordiskfond Clinical Distinguished Investigator 2023 - and the DKK 10 mio that follows! 🎉
Jacob receives the award for his research with mechanical circulatory support in cardiogenic shock.
@OUHhospital
@RigsHeart
